Navigation Links
A Recent Study by ITG's Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
Date:6/1/2011

NEW YORK, June 1, 2011 /PRNewswire/ -- A study published this week by ITG's Majestic Market Research revealed that Novartis' recently approved drug, Gilenya, continues to steal share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  Gilenya came onto the market in late September 2010 as the first FDA-approved oral disease-modifying MS drug.  Despite negative sentiment around Gilenya's lengthy initiation process, neurologists are embracing the new drug at an impressive rate.  Real time data from ITG's proprietary physician panel indicate that Gilenya was the disease-modifying treatment of choice for 20% of new written MS prescriptions in April.  Furthermore, surveyed neurologists indicated that their prescribing of Gilenya will increase significantly over the course of 2011 as they continue to shift inadequate responders from other MS therapies to the new drug.

The study takes an in-depth look at how Gilenya's multi-step initiation process is impacting neurologists' use of the drug.  According to neurologists, new treatment starts for Gilenya typically take between three to six weeks and involve the scheduling and organization of prescreening tests and ongoing monitoring for adverse events.  

Physicians reported that Novartis plays an important role in facilitating these steps. In fact, 63% of Gilenya prescribers indicated that they receive support from Novartis during this process, and 25% of them classified this assistance as superior to what competing companies offer for their products.  

By comparison, neurologists appear unable to get over similar concerns about Acorda Therapeutics' Ampyra, which was launched in March 2010 as the first FDA approved drug to improve walking in MS patients. Like Gilenya, Ampyra is associated with an onerous initi
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
5. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
6. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
7. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
11. Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... ANGELES , Oct. 30, 2014 Migranade, ... Relief will be available to the 36 million U.S. ... a platform technology that targets the actual cause of ... medications attack pain and not the source Migranade is ... medication category. MIGRANADE Migraine Relief is available at ...
(Date:10/31/2014)... -- AbbVie (NYSE: ABBV ) today announced ... 30, 2014. "Our third-quarter results ... double-digit growth from HUMIRA and several other key ... in the quarter excluding lipids," said Richard A. ... exceeded our outlook for the quarter and have ...
(Date:10/30/2014)... 30, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... and the United States , ... the Tel Aviv area of ... WuXi,s broad platform of integrated R&D services to local ...
Breaking Medicine Technology:Game Changing Migraine Medication To Be Available November 2014 2AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2
... mass index (BMI) should be taken into account when assessing ... Cancer Treatment Centers of America (CTCA), ... of vitamin D compared to non-obese patients. , , ... , The association between vitamin D and obesity remains unsettled ...
... Calif., June 12 Masimo (Nasdaq: MASI ... and Low-Perfusion pulse oximetry, announced today that three new ... Masimo PVI as a noninvasive and continuous measure of ... at the European Society of Anaesthesiology (ESA) Annual Congress ...
Cached Medicine Technology:Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6
(Date:10/31/2014)... 31, 2014 With all the preparations ... optometrist feels they may overlook one critical area – ... like concentration, school performance and even behavior. Typical children’s ... to identify progressive vision problems, and to address this ... a new initiative: The Awesome Eyes Student Vision Program. ...
(Date:10/31/2014)... 31, 2014 Energy Textiles has recently ... new gear is now available online, and Energy Textile ... of Celliant infrared-active athletic gear over compression gear. , ... contract has been signed for Under Armour to provide ... next eight years. In light of this decision, Energy ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Sleep apnea may make ... where you parked your car or left your house keys, ... severe sleep apnea showed that this ability -- called spatial ... movement (REM) sleep, even when other stages of sleep weren,t ... which dreams typically occur. "We,ve shown for the first ...
(Date:10/31/2014)... cost, patients with early stage breast cancer may ... proton therapy versus whole breast irradiation (WBI), according ... MD Anderson Proton Therapy Center. , ... patient characteristics, researchers used Medicare reimbursement codes to ... partial and whole breast irradiation therapies and treatment ...
(Date:10/31/2014)... one out of four older Americans say that either ... unwanted medical treatment, according to the latest issue of ... Aging Report ( PP&AR ), which goes on ... when they fail to honor patients, end-of-life health care ... Illness Care: Issues and Options ," features 12 articles ...
Breaking Medicine News(10 mins):Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Advance directives can benefit patients, families, and health care system 2
... N.Y., Jan. 10 With an eye to ... Mattress,Inc. ( http://www.bragada.com ) is now packing its ... high-end features than before., All Bragada Luxury ... vera built into the fabric. One of the ...
... ALF Regarding Her Battle ... with Hepatitis C, NEW ... dedicated to advocating on behalf of,Americans with liver disease, is proud announce ... of liver disease,including hepatitis C. To help spread the word about ALF,s ...
... to Compound Commonly Prescribed Hormone,Treatments, Use the Term ... In a series of,warning letters to compounding pharmacies ... has asserted a policy that would deny hundreds ... hormones,commonly, substituting its judgment for that of doctors. ...
... first Southern-style canned product ... American Heart Association, COLUMBUS, Ohio, Jan. 9 ... low fat and meatless, were the first,product line of ... savory,taste. Now, heart-healthy Sensibly Seasoned products also bear the ...
... Drew,s Question for Parents to be Featured on Yahoo! Answers -, ... Substance ... Abuse Treatment, NEW YORK, Jan. 9 ... of VH1,s new reality,series "Celebrity Rehab With Dr. Drew," is helping support ...
... affects 1% of all cases of developmental disorder, researchers say ... 16 appear to raise children,s risk for developing autism, a ... of autism researchers, pinpoints one of the causes of a ... its origins as it is in its symptoms. Not only ...
Cached Medicine News:Health News:Bragada(R) Luxury Mattress, Inc. Upgrades Luxury and Ultra Luxury Collections 2Health News:EHE International Supports the American Liver Foundation's Efforts at Raising Awareness for Hepatitis 2Health News:FDA Asserts New Policy to Restrict Women's Access to Bioidentical Hormones 2Health News:Glory Foods Receives Heart Healthy Certification 2Health News:Dr. Drew Joins the Partnership for a Drug-Free America in Supporting TimeToTalk(TM) 2Health News:Dr. Drew Joins the Partnership for a Drug-Free America in Supporting TimeToTalk(TM) 3Health News:Dr. Drew Joins the Partnership for a Drug-Free America in Supporting TimeToTalk(TM) 4Health News:Chromosome Abnormalities Raise Risk for Autism 2Health News:Chromosome Abnormalities Raise Risk for Autism 3Health News:Chromosome Abnormalities Raise Risk for Autism 4
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: